ESPE Abstracts

Introduction: Congenital hyperinsulinism (CHI) is a rare disease affecting 1 in 25,000 to 50,000 newborns that requires emergent treatment of recurrent hypoglycemia to prevent neurological sequelae. There is a high unmet need for novel treatments due to the limited effectiveness and adverse effects associated with the current standard of care medications, namely diazoxide and somatostatin analogues.Methods: Efpegerglucag...